Perceptive Capital Solutions shareholders are set to vote on the transaction during an extraordinary general meeting scheduled for July 9, 2026. The company has already mailed proxy statements to all shareholders of record as of June 12, marking the final administrative push before the anticipated close of the deal in July.

Upon completion of the merger, the combined entity will operate as Freenome, Inc. The company specializes in early-stage cancer detection, utilizing a multiomics platform that integrates blood-based biomarkers with machine learning to identify disease markers. Perceptive Capital, led by Chairman Joseph Edelman and CEO Adam Stone, is the investment vehicle facilitating this transition for the Brisbane-based biotech firm.